Latest news and press releases about Anika Therapeutics, Inc. (ANIK): earnings reports, analyst upgrades/downgrades, product launches, partnerships and regulatory filings. Stay updated on every market-moving event.
Anika Therapeutics, Inc. is a company dedicated to joint preservation, innovating and providing early intervention orthopedic care across the globe, including the United States and Europe. Their core focus areas include osteoarthritis (OA) pain management, regenerative solutions, soft tissue repair, and advanced bone-preserving joint technologies.
Price
| Price | $21.03 |
| Market Cap | $281M |
| Exchange | NASDAQ |
| Country | US |
Valuation Ratios
| Price / Book | 2.02 |
| EV / EBITDA | 97.19 |
| Dividend Yield | 0.00% |
Profitability
| Return on Equity | -2.70% |
| Return on Invested Capital | -3.17% |
| Return on Assets | -2.06% |
| Gross Margin | 62.16% |
| Operating Margin | -4.24% |
| Net Margin | -3.14% |
Related companies: ANIX · APYX · ARAY · AVR · LNSR · LUCD · MXCT
Explore sector: Healthcare · Medical - Specialties
More sections of ANIK: Overview · Financials · Valuation · Statistics · Estimates · Technical · Ownership · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks